Broad-spectrum ADC new drug DS-8201 strongly treats HER2+ cancers
- Stem Cell Therapy for Inflammatory Bowel Disease
- How about the safety and efficacy of novel CAR-T therapies?
- Even mild infection with COVID-19 can trigger long-lasting neuroinflammation
- Amyotrophic Lateral Sclerosis (ALS): Two new drugs failed in clinical trials!
- The “magic drug” metformin may make people live to 120 years old!
- Why do most smokers not get lung cancer?
Broad-spectrum ADC new drug DS-8201 strongly treats HER2+ cancers
- COVID “Arcturus” XBB.1.16: The first death in U.S.
- Dual CRISPR therapy + long-acting antiretroviral drugs to clear HIV from the body
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
Broad-spectrum ADC new drug DS-8201 strongly treats HER2+ cancers.
On October 4, 2021, FDA granted DS-8201 (Enhertu) breakthrough therapy designation for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received one or more anti-HER2-based regimens. This is the fourth breakthrough therapy designation that DS-8201 has obtained.
In fact, the comprehensive clinical research results of Enhertu (DS8201), the heavy antibody-drug conjugate (ADC), can be described as “strength grabbing the spotlight”. Although the line of treatment started in the future, the clinical data is all over breast, gastric, and gastric cancer. Lung cancer and colorectal cancer have brought new treatment hopes to patients with multiple cancers of HER2 mutations, showing extraordinary potential!
At the European Society of Medical Oncology (ESMO) annual meeting held on September 16-21 not long ago, the results of more than one DS-8201 studies were refreshed again, sweeping the four major cancer types of lung, breast, gastrointestinal, and undiminished style. Today, the editor of Cancer Free Home will sort out the latest research progress of this broad-spectrum ADC new drug DS-8201.
The risk of recurrence is reduced by 72%, DS-8201 challenges the second-line standard treatment for breast cancer
The results of the phase 3 trial of DESTINY-Breast03 identified this time are the first multi-center, open, randomized, head-to-head comparison of the efficacy and safety of ADC drugs (DS8201 and T-DM1) in the treatment of HER2-positive advanced breast cancer. Phase III clinical study.
Patients with unresectable or metastatic HER2-positive breast cancer who had previously been treated with trastuzumab (Herceptin) and taxanes in an advanced or metastatic setting were included. It is worth noting that these patients are allowed to have clinically stable, treated brain metastases.
The trial data submitted during the ESMO conference in 2021 showed that the PFS of DS8201 assessed by the investigator was 25.1 months (95% CI, 22.1-NE), while T-DM1 was 7.2 months (95% CI, 6.8-8.3) (HR, 0.27); neither the study group nor the control group reached the median survival time.
The above data shows that, compared with TDM1, DS-8201 can reduce the risk of disease progression or death in patients with HER2-positive metastatic breast cancer by up to 72%!
In addition, DS-8201 confirmed an objective response rate of 79.7%, while TDM1 was 34.2%. This shows that the efficacy of DS-8201 is 2.33 times that of TDM1!
Among the responses to DS-8201, complete remission was 16.1%, partial remission was 63.3%, disease was stable 16.9%, and only 1.1% of patients had disease progression!
Disease control rate is 100%! FDA grants fast track to HER2+ breast cancer new drug ARX788
For HER2-positive breast cancer, cancer patients actually have more choices.
In January 2021, the FDA granted a new antibody-conjugated drug ARX788 fast track designation, aimed at accelerating the marketing of this advanced anti-cancer therapy, and bringing better treatment to patients with advanced HER2-positive breast cancer who have progressed after first-line treatment choose. This is also an important milestone for ARX788. It is expected that ARX788 will be approved by the FDA as soon as possible.
The results of this clinical trial were announced at the San Antonio Breast Cancer Symposium in December 2020. It is worth mentioning that in the Phase 1 trial of HER2-positive breast cancer in China, the objective response rate was as high as 74%, among which 19 patients There were 14 responders, and the disease control rate was as high as 100%.
In the phase 1 HER2-positive pan-tumor trials conducted in the United States and Australia, the objective response rate was 67%, 2 out of 3 patients responded, and the disease control rate was 100%.
At present, a number of clinical studies of ARX788 have been initiated around the world. One of them is a clinical study on HER2-positive breast cancer patients who have failed first-line treatments such as Herceptin. Patients are being recruited. Cancer friends who are interested in participating can contact Cancer-Free The Department of Homeland Medicine (400-626-9916) conducts a preliminary assessment.
The disease control rate reached 81%! DS-8201 has become a dark horse for the treatment of advanced gastric cancer
Studies have shown that about 1/5 of gastric cancer patients are HER2 positive. Therefore, in the Phase II clinical trial of DESTINY-Gastric01, the effectiveness of DS-8201 in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma was evaluated.
At the ESMO conference in 2021, the results of DESTINY-Gastric02 have also been further updated. The trial enrolled 79 patients, each with 6.4mg/kg Q3W standard medication. These patients had previously received 2 or more regimens (including 5-FU, platinum-containing chemotherapy, trastuzumab).
As of April 9, 2021, the study has reached its primary and key secondary endpoints:
Among 79 evaluable patients, the objective response rate of DS8201 for HER2+ gastric cancer or GEJ patients evaluated by the independent central review (ICR) was 38%, and the disease control rate could reach 81%.
The median progression-free survival was 5.5 months, and the median duration of remission was 8.1 months.
With an objective response rate of 92.3%, DS-8201 leads the targeted therapy of lung cancer and sets off an innovative revolution
The DESTINY-Lung01 study released at the ASCO conference last year is aimed at HER2 mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC) that has often received one or more systemic treatments and has disease progression. The patients started, and most of them had received platinum-containing chemotherapy (90.5%) and anti-PD-1 or PD-L1 therapy (54.8%).
The results of the study showed that 61.9% of patients receiving DS-8201 monotherapy (6.4mg/kg) achieved tumor remission, and the disease control rate (90.5%) and median progression-free survival (14.0 months) were significantly improved.
The data was further updated at this year’s ESMO conference. Among the HER2 mutant patients, 1 patient achieved complete remission, 49 achieved partial remission, 34 had stable disease, 3 had disease progression, and 4 could not be assessed. Objective remission was confirmed The rate is 54.9%, and the disease control rate is as high as 92.3%!
The median progression-free survival of patients was 8.2 months, and the median overall survival was 17.8 months.
Studies have also shown that regardless of the type of HER2 gene mutation, patients may benefit from the treatment of DS-8201.
Disease control rate reached 83%, DS8201 broke the shackles of HER2-positive colorectal cancer
DESTINY-CRC01, announced at the ASCO meeting in 2020, is a phase II clinical trial for HER2-positive, unresectable and/or metastatic colorectal cancer patients who have previously received two or more standard treatments.
The results of this test showed that after DS-8201 monotherapy, the patient’s objective tumor remission rate was 45.3%, of which the complete remission rate was 1.9%, the partial remission rate was 43.4%, and the disease control rate (DCR) reached 83.0%. The median progression-free survival (PFS) was 6.9 months.
At present, there is no definite therapeutic drug approved for HER2-positive colorectal cancer patients, and DS-8201’s unique advantages in tumor remission rate and disease control rate will break through the shackles of HER2-positive colorectal cancer treatment and bring it to the majority of patients new Hope.
“Targeting + chemotherapy” join forces to create a new anti-cancer drug DS-8201
DS8201, a HER2 antibody + irinotecan chemotherapeutic drug conjugate, belongs to the ADC type drug type (antibody conjugate drug). It consists of two parts: the first part is an antibody against the HER2 target, which can accurately identify and bind tumor cells with high or even low expression of HER2; the second part is the highly toxic chemotherapeutic drug irinotecan. This design allows the antibody to take the chemotherapeutics to find the tumor cells, and then accurately poison the tumor cells to kill them.
The picture shows the design structure of DS-8201. The small orange balls in the picture are chemotherapy drugs (source dsi.com)
This drug design combines the precision of targeted drugs and the high efficiency of chemotherapeutics, which not only avoids the toxic and side effects of systemic use of chemotherapeutics, but also has stronger killing ability than targeted drugs alone, which can kill two birds with one stone.
(source:internet, reference only)
Disclaimer of medicaltrend.org